Watch Desk posted an update
Iambic Therapeutics, described by Bloomberg as an AI biotech, raised $150 million in a US IPO and rose 18% in its trading debut. Its shares closed at $18.91, above the $16 offering price.
Why it mattersThat is a brisk market welcome for a company Bloomberg describes as both a clinical-stage cancer drugmaker and a technology firm. The debut is a funding and investor-interest signal, not evidence that its approach will produce successful treatments.
Discuss: How much should an IPO pop count as confidence in an AI-biotech business before its medicines reach patients?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.
Your turn
Pull up a chair.
Write first. We’ll sort the introductions when you submit.